Key result
An editorial discusses the reanalysis of deaths in the Anturane Reinfarction Trial among 1475 patients with acute myocardial infarction.
Why the study?
Does sulfinpyrazone reduce deaths in patients with acute myocardial infarction?
Does sulfinpyrazone reduce deaths in patients with acute myocardial infarction?
This editorial discusses the blinded reanalysis of mortality outcomes from the Anturane Reinfarction Trial in patients with acute myocardial infarction.
This issue of the Journal carries another chapter in the saga of the Anturane Reinfarction Trial. This report1 presents the results of a special committee chaired by Dr. Bertram Pitt that was given the responsibility of reanalyzing in blinded fashion all the deaths that occurred in this trial to determine whether the results reported earlier2 , 3 could be reproduced.The steps leading up to this latest undertaking were summarized in an earlier Journal editorial,4 but it is worthwhile to retrace them here. In 1978 the Anturane Reinfarction Trial Study Group published a preliminary report on 1475 eligible patients with acute myocardial . . .
No takes yet. Share an insight, caveat, or question.
William B. Hood (1982) conducted an editorial in acute myocardial infarction (n=1,475). Sulfinpyrazone was evaluated on deaths. An editorial discusses the reanalysis of deaths in the Anturane Reinfarction Trial among 1475 patients with acute myocardial infarction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: